This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued in the second.
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
by Zacks Equity Research
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
by Zacks Equity Research
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
by Zacks Equity Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
5 Stocks in S&P 500 ETF That Gained Last Week
by Sweta Killa
The S&P 500 wrapped up its worst week since March 2020, tumbling 5.8%. Despite the massive decline, some of the stocks in SPY¿¿¿s portfolio have risen.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
by Kinjel Shah
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
by Zacks Equity Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
by Zacks Equity Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
by Zacks Equity Research
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.
Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension
by Zacks Equity Research
The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
by Zacks Equity Research
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
The Zacks Analyst Blog Highlights Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group
by Zacks Equity Research
Oracle, Union Pacific, Ford Motor, Biogen and Expedia Group have been included in this Analyst Blog.
Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates. Stock moves up in response to the results.
Analyst Upgrades and Research Reports for Oracle, Union Pacific, Ford & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Union Pacific Corporation (UNP), and Ford Motor Company (F).
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig
by Zacks Equity Research
Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.